In:
Journal of Antimicrobial Chemotherapy, Oxford University Press (OUP), ( 2023-11-24)
Abstract:
Integrase strand transfer inhibitors (INSTIs) are associated with excessive weight gain among a subset of persons with HIV (PWH), due to unclear mechanisms. We assessed energy intake (EI) and expenditure (EE) following switch off and onto INSTIs. Methods PWH with & gt;10% weight gain on an INSTI-based regimen switched INSTI to doravirine for 12 weeks, then back to INSTI for 12 weeks while keeping their remaining regimen stable. Twenty-four-hour EE, EI and weight were measured on INSTI, following switch to doravirine, and upon INSTI restart. Mixed models analysed changes over time. Results Among 18 participants, unadjusted 24 h EE decreased by 83 (95% CI −181 to 14) kcal following switch to doravirine, and by 2 (−105 to 100) kcal after INSTI restart; energy balance (EE−EI) increased by 266 (−126 to 658) kcal from Week 0 to Week 12, and decreased by 3 (−429 to 423) kcal from Week 12 to Week 24. Trends toward weight loss occurred following switch to doravirine [mean −1.25 (−3.18 to 0.69) kg] and when back on INSTI [−0.47 (−2.45 to 1.52) kg] . Trunk fat decreased on doravirine [−474 (−1398 to 449) g], with some regain following INSTI restart [199 (−747 to 1145) g] . Fat-free mass decreased on doravirine [−491 (−1399 to 417) g] and increased slightly after INSTI restart [178 (−753 to 1108) g] . Conclusions Among PWH with & gt;10% weight gain on an INSTI, switch to doravirine was associated with a trend towards decreases in 24 h EE, weight, trunk fat mass and fat-free mass. Observed changes were not significant, but suggest a mild weight-suppressive effect of doravirine among PWH.
Type of Medium:
Online Resource
ISSN:
0305-7453
,
1460-2091
Language:
English
Publisher:
Oxford University Press (OUP)
Publication Date:
2023
detail.hit.zdb_id:
1467478-6
SSG:
15,3
Permalink
